Susquehanna International Group
BTAI icon

Susquehanna International Group’s BioXcel Therapeutics BTAI Stock Holding History

Susquehanna International Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-781
Closed -$7.63K – 12233
2024
Q3 		$7.63K Sell
781
-7,482
-91% -$101K ﹤0.01% 11737
2024
Q2 		$169K Buy
8,263
+407
+5% +$13.6K ﹤0.01% 10570
2024
Q1 		$354K Sell
7,856
-4,063
-34% -$194K ﹤0.01% 9310
2023
Q4 		$563K Buy
11,919
+5,000
+72% +$278K ﹤0.01% 8367
2023
Q3 		$280K Sell
6,919
-10,731
-61% -$1.08M ﹤0.01% 9501
2023
Q2 		$1.88M Buy
17,650
+15,650
+783% +$5.21M ﹤0.01% 5277
2023
Q1 		$597K Sell
2,000
-200
-9% -$85.4K ﹤0.01% 8126
2022
Q4 		$756K Sell
2,200
-888
-29% -$215K ﹤0.01% 6808
2022
Q3 		$584K Sell
3,088
-1,818
-37% -$422K ﹤0.01% 8066
2022
Q2 		$1.04M Buy
4,906
+2,087
+74% +$439K ﹤0.01% 6461
2022
Q1 		$943K Sell
2,819
-1,112
-28% -$322K ﹤0.01% 7280
2021
Q4 		$1.28M Sell
3,931
-4,144
-51% -$1.78M ﹤0.01% 6615
2021
Q3 		$3.92M Sell
8,075
-1,550
-16% -$682K ﹤0.01% 4402
2021
Q2 		$4.47M Buy
9,625
+5,225
+119% +$2.85M ﹤0.01% 4237
2021
Q1 		$3.04M Sell
4,400
-5,631
-56% -$4.53M ﹤0.01% 4920
2020
Q4 		$7.42M Buy
10,031
+6,593
+192% +$5.14M ﹤0.01% 2865
2020
Q3 		$2.38M Sell
3,438
-6,450
-65% -$4.84M ﹤0.01% 4285
2020
Q2 		$8.39M Buy
9,888
+5,475
+124% +$3.57M ﹤0.01% 2352
2020
Q1 		$1.58M Buy
+4,413
New +$1.59M ﹤0.01% 4403

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's BTAI Position: Q1 2025 in Review

Susquehanna International Group sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2,158 shares — an estimated $12.9K sold.

Susquehanna International Group first reported a position in BTAI in Q2 2020 and held it in 18 quarters. The position peaked at $9.99M in Q3 2020. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Susquehanna International Group reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 2,158 BioXcel Therapeutics shares in Q1 2025, an estimated $12.9K.
  • Susquehanna International Group first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 18 quarters.
  • Susquehanna International Group's BioXcel Therapeutics position peaked at $9.99M in Q3 2020.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.